Maryke Fehlau
Papers
1
Total Citations
6
H-Index
1
About
Maryke Fehlau is a biochemist whose research centers on nucleoside kinases—enzymes critical for activating nucleoside analogue drugs used in cancer and antiviral therapies. Her major contribution lies in developing a semi-automated, high-throughput substrate screening assay for these kinases, a methodological breakthrough that enables rapid, systematic characterization of enzyme specificity. This work, published in 2021 and garnering 6 citations, directly addresses a bottleneck in drug design and the in vitro production of nucleotide analogues. By creating a platform that can efficiently profile diverse nucleoside kinases, Fehlau has provided researchers with a powerful tool to identify optimal enzyme-substrate pairs, accelerating the development of more effective prodrugs. Her approach bridges fundamental enzymology with applied pharmaceutical development, offering a practical solution for screening enzymes with different substrate preferences. This achievement marks her as a rising contributor to the field of nucleoside metabolism and drug discovery, where her assay holds promise for streamlining the evaluation of new therapeutic candidates and biocatalytic processes.
Research Focus
Key Achievements
Top Papers
- 1